Heat shock proteins: A potential anticancer target

Current Drug Targets

Volumn 12, Issue 14, 2011, Pages 2001-2008

  Sankhala, Kamalesh K ^a   Mita, Monica M ^a   Mita, Alain C ^a   Takimoto, Chris H ^b  

^a CTRC Institute for Drug Development   (United States)

^b Ortho Biotech Oncology Research and Development   (United States)

Author keywords

17 AAG; Apoptosis; Avespimycin; Cancer hallmarks; CNF 2024; CNF 1010; Geldanamycin; Hsp inhibitors; Hsp90; Retaspamycin; SNX 5422; Tanespamycin

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; BORTEZOMIB; CELL PROTEIN; CNF 1010; CNF 2024; CYCLIN DEPENDENT KINASE; DOCETAXEL; GANETESPIB; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; IMATINIB; RETASPIMYCIN; SNX 2122; SNX 5422; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; DIARRHEA; DIZZINESS; DRUG SAFETY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPONATREMIA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEOPLASM; PANCREATITIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SYNCOPE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS;

EID: 84855860803     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798829339     Document Type: Article

References (107)

1. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1996; 1(2): 97-8.
2. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem 1982; 257(24): 14949-59.
3. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S. hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol 1989; 9(9): 3919-30.
4. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev 2005; 5(10): 761-72.
5. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006; 1(5): 279-84.
6. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Exp Opin Biol Ther 2002; 2(1): 3-24.
7. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91(18): 8324-8.
8. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36(4): 305-15.
9. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006; 13(Suppl 1): S125-35.
10. Schweinfest CW, Graber MW, Henderson KW, et al. Cloning and sequence analysis of Hsp89alpha DeltaN, a new member of theHsp90 gene family. Biochim Biophys Acta 1998; 1398(1): 18-24.
11. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006; 75: 271-94.
12. Scheufler C, Brinker A, Bourenkov G, et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000; 101(2): 199-210.
13. Pratt WB, Galigniana MD, Harrell JM, DeFranco DB. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 2004; 16(8): 857-72.
14. Prodromou C, Panaretou B, Chohan S, et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 2000; 19(16): 4383-92.
15. Roe SM, Ali MM, Meyer P, et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004; 116(1): 87-98.
16. Ali MM, Roe SM, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006; 440(7087): 1013-7.
17. Demand J, Alberti S, Patterson C, Hohfeld J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol 2001; 11(20): 1569-77.
18. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001; 3(1): 93-6.
19. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008; 13(1-2): 38-43.
20. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425(6956): 407-10.
21. Sawai A, Chandarlapaty S, Greulich H, et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes egfr mutant tumors to paclitaxel. Cancer Res 2008; 68(2): 589-96.
22. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008; 68(14): 5827-38.
23. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 2002; 168(4 Pt 1): 1412-4.
24. Xu W, Mimnaugh E, Rosser MF, et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001; 276(5): 3702-8.
25. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8(5): 986-93.
26. Braconi C, Bracci R, Bearzi I, et al. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol 2008; 19(4): 706-10.
27. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Develop 2007; 17(1): 3-7.
28. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24(29): 4764-74.
29. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103(3): 1078-84.
30. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66(18): 9153-61.
31. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 2009; 11(4): 307-13.
32. Nielsen TO, Andrews HN, Cheang M, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004; 64(1): 286-91.
33. Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007; 13(21): 6459-68.
34. Naoe T, Kiyoe H, Yamamoto Y, et al. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chem Pharmacol 2001; 48(Suppl 1): S27-30.
35. Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002; 16(8): 1535-40.
36. Al Shaer L, Walsby E, Gilkes A, et al. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol 2008; 141(4): 483-93.
37. Sankhala KK, Papadopoulos KP. Future options for imatinib mesilate-resistant tumors. Expert Opin Invest Drugs 2007; 16(10): 1549-60.
38. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100(8): 3041-4.
39. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev 2002; 2(7): 489-501.
40. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277(42): 39858-66.
41. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21(8): 1159-66.
42. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97(20): 10832-7.
43. Soga S, Sharma SV, Shiotsu Y, et al. Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother Pharmacol 2001; 48(6): 435-45.
44. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95(8): 625-7.
45. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
46. Jaiswal RK, Weissinger E, Kolch W, Landreth GE. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem 1996; 271(39): 23626-9.
47. Schulte TW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Molec Cell Biol 1996; 16(10): 5839-45.
48. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001; 7(7): 2076-84.
49. Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007; 67(7): 2932-7.
50. Beliakoff J, Bagatell R, Paine-Murrieta G, et al. Hormonerefractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003; 9(13): 4961-71.
51. Vanaja DK, Mitchell SH, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chap 2002; 7(1): 55-64.
52. Saporita AJ, Ai J, Wang Z. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007; 67(5): 509-20.
53. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998; 17(25): 3237-45.
54. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19(16): 4310-22.
55. Lewis J, Devin A, Miller A, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptorinteracting protein (RIP), and blockage of tumor necrosis factorinduced nuclear factor-kappaB activation. J Biol Chem 2000; 275(14): 10519-26.
56. Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002; 9(2): 401-10.
57. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282(5392): 1318-21.
58. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev 2002; 2(1): 38-47.
59. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alphadegradative pathway. J Biol Chem 2002; 277(33): 29936-44.
60. Gradin K, McGuire J, Wenger RH, et al. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Molec Cell Biol 1996; 16(10): 5221-31.
61. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Molec Cancer Therap 2006; 5(3): 522-32.
62. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4(12): 915-25.
63. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109(7): 863-7.
64. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007; 67(5): 2081-8.
65. Bishop SC, Burlison JA, Blagg BS. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 2007; 7(4): 369-88.
66. Ochel HJ, Schulte TW, Nguyen P, Trepel J, Neckers L. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Molec Genet Metab 1999; 66(1): 24-30.
67. Le Boeuf F, Houle F, Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 2004; 279(37): 39175-85.
68. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004; 6(6): 507-14.
69. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12(1): 97-9.
70. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68: 67-108.
71. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene productdependent G1 arrest. Cancer Res 2000; 60(14): 3940-6.
72. Prince T, Sun L, Matts RL. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 2005; 44(46): 15287-95.
73. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11(5): 1921-9.
74. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33(5): 787-91.
75. Holt SE, Aisner DL, Baur J, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Develop 1999; 13(7): 817-26.
76. Keppler BR, Grady AT, Jarstfer MB. The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity. J Biol Chem 2006; 281(29): 19840-8.
77. Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Topics Med Chem 2006; 6(11): 1163-71.
78. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42(4): 273-9.
79. Banerji U, Walton M, Raynaud F, et al. Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11(19 Pt 1): 7023-32.
80. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23(6): 1078-87.
81. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005; 11(9): 3385-91.
82. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13(6): 1775-82.
83. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25(34): 5410-7.
84. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27(21): 3518-25.
85. Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008; 26(Suppl): abstr 1027.
86. Saif MW, Erlichman C, Dragovich T, et al. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. J Clin Oncol 2006; 24(18 Suppl): 10062.
87. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006; 103(46): 17408-13.
88. Demetri GD, George S, Morgan JA, et al. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. J Clin Oncol 2007; 25(18 Suppl): 10024.
89. Study evaluating IPI-504 in patients with Gastrointestinal Stromal Tumors (GIST) following failure of at least Imatinib and Sunitinib. 2009; NCT00688766. www.clinicaltrials.gov
90. Sequist LV, Gettinger S, Natale R, et al. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J Clin Oncol 2009; 27(15S): abstr 8073.
91. Riely GJ, Stoller R, Egorin M, et al. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. J Clin Oncol 2009; 27(15S): 3547.
92. Miller K, Rosen LS, Modi S, et al. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T). J Clin Oncol 2007; 25(18 Suppl): 1115.
93. Flaherty KT, Gore L, Avadhani A, et al. Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies. J Clin Oncol 2007; 25(18 Suppl): 14059.
94. Modi S, MK, Rosen LS, Schneider B, Chap L, Zhong Z, Kersey K, Hannah AL, Hudis C. Alvespimycin (KOS-1022) and trastuzumab (T): Activity in HER2+ metastatic breast cancer (MBC). Breast Cancer Symp 2007; Abstract no.165.
95. Lancet J, Gojo I, Baer M, et al. Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of the Hsp-90 inhibitor, KOS-1022 (17-DMAG), in patients with refractory hematological malignancies. J Clin Oncol 2006; 24(18 Suppl): 2081.
96. Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006; 7(6): 534-41.
97. Gaspar N, Sharp SY, Pacey S, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009; 69(5): 1966-75.
98. McCollum AK, TenEyck CJ, Stensgard B, et al. P-Glycoproteinmediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008; 68(18): 7419-27.
99. Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Topics Med Chem 2006; 6(11): 1183-91.
100. McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Topics Med Chem 2006; 6(11): 1193-203.
101. Elfiky A, Saif MW, Beeram M, et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 2008; 26(15 Suppl): 2503.
102. An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST). 2009; NCT00618319. www.clinicaltrials.gov
103. Sessa C, Sharma SK, Britten CD, et al. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2009; 27(15S): 3532.
104. www.clinicaltrials.gov. Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. wwwclinicaltrialsgov. 2009; NCT00526045.
105. Bryson JC, Infante JR, Ramanathan RK, et al. A Phase 1 doseescalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. J Clin Oncol 2008; 26(15 Suppl): 14613.
106. www.clinicaltrials.gov. A Phase 1/2 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia. wwwclinicaltrialsgov. 2009; NCT00964873.
107. Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors. 2009; NCT00687934. www.clinicaltrials.gov